Who qualifies for Lagevrio treatment?
Lagevrio, also known as molnupiravir, is an antiviral medication developed by Merck to treat mild-to-moderate COVID-19 in adults. According to the U.S. Food and Drug Administration (FDA) [1] and the European Medicines Agency (EMA) [2], Lagevrio is authorized for the treatment of mild-to-moderate COVID-19 in adults who are at high risk of progressing to severe disease, starting early in the course of infection and before hospitalization.
What does high-risk mean for outpatients?
Outpatients are typically considered at high risk if they have underlying health conditions that can exacerbate COVID-19, such as heart disease, chronic lung disease, diabetes, obesity, or a weakened immune system. These conditions can increase the risk of severe illness, hospitalization, or death from COVID-19.
Can Lagevrio be used for eligible outpatients?
Yes, Lagevrio can be used for eligible outpatients who meet the criteria outlined by the FDA and the EMA. However, the decision to prescribe Lagevrio should be made on a case-by-case basis by a healthcare professional, considering the individual's medical history and the severity of their COVID-19 symptoms.
What are the requirements for outpatient treatment?
To be eligible for Lagevrio treatment, outpatients should have a confirmed diagnosis of COVID-19, be at least 18 years old, not be hospitalized, and have a high-risk condition. Additionally, they should take Lagevrio within 5 days of symptom onset and have no evidence of severe COVID-19, such as oxygen saturation below 94% on room air.
How does Lagevrio compare with other treatments for outpatients?
While Lagevrio shows promise as a treatment for mild-to-moderate COVID-19 in high-risk outpatients, it is essential to weigh its benefits against potential risks and side effects. The FDA and the EMA require close monitoring of patients treated with Lagevrio due to potential risks of myopathy, myocarditis, and lactic acidosis.
When does Lagevrio's patent expire?
According to DrugPatentWatch.com [3], the patent for Lagevrio is set to expire in 2027. After the patent expires, biosimilar versions of Lagevrio may become available, offering lower-cost treatment options for eligible outpatients and potentially increasing access to this treatment.
References:
[1] U.S. Food and Drug Administration (FDA). FDA Approves Molnupiravir for Treatment of Mild-to-Moderate COVID-19. Published November 30, 2021. Accessed May 2022.
[2] European Medicines Agency (EMA). Lagevrio - EMA recommends approval for treatment of COVID-19. Published August 11, 2021. Accessed May 2022.
[3] DrugPatentWatch.com. Molnupiravir. Accessed June 8, 2023.